• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2023.18086

Complications of liver cirrhosis and matrix metalloproteinases: clinical relationships

[Internal diseases]
Temirlan Ruslanovich Dudov; Pavel Koroy; Alexandr Yagoda;

The paper presents the resaults of study is to study the relationship of the matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) with the features of the course of liver cirrhosis (LC). 159 patients with LC (53 women, 106 men) aged from 26 to 64 years were examined. The control group consisted of 72 practically healthy people. The blood content of TIMP-1, MMP-1 and MMP-9 was determined; the ratio of TIMP-1/MMP-1, TIMP-1/MMP-9 was calculated. There was an increase in the concentration of MMP-1 and TIMP-1 in the blood, the ratio of TIMP-1/MMP-9 and a decrease in the values of MMP-9, TIMP-1/MMP-1 in LC. Prognostically unfavorable variants of the disease (Child-Pugh B/C classes, values of MELD scale ≥9 points, sub- and decompensated portal hypertension, the presence of ascites or hepatic encephalopathy) were characterized by a higher content of TIMP-1, MMP-1, MMP-9 in the blood and lower values of TIMP-1/MMP-1, TIMP-1/MMP-9. In patients with LC with previous bleeding from the esophageal varices, a higher concentration of MMP-1 in the blood and lower values of TIMP-1/MMP-1 were recorded. Thus, the increase in serum levels of matrix metalloproteinases associated with the manifestations of portal hypertension indicates their role in the formation of complications of the disease.

Download

References:
1. Geervliet E., Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells. 2020;9:1212. https://doi.org/10.3390/cells9051212
2. Ye F., Zhai M., Long J., Gong Y., Ren C. [et al.]. The burden of liver cirrhosis in mortality: Results from the global burden of disease study. Front. Public Health. 2022;10:909455. https://doi.org/10.3389/fpubh.2022.909455
3. Cheemerla S., Balakrishnan M. Global epidemiology of chronic liver disease. Clin. Liver Dis. (Hoboken). 2021;17(5):365-370. https://doi.org/10.1002/cld.1061
4. Seto W. K., Mandell M. S. Chronic liver disease: global perspectives and future challenges to delivering quality health care. PLoS One. 2021;16(1):e0243607. https://doi.org/10.1371/journal.pone.0243607
5. D’Amico G., Bernardi M., Angeli P. Towards a new definition of decompensated cirrhosis. J. Hepatol. 2022;76(1):202-207. https://doi.org/10.1016/j.jhep.2021.06.018
6. Koroy P. V., Dudov T. R., Yagoda A. V., Sarithala V. J. Matrix metalloproteinases: the role in evolution of liver disea es (literature review). Medical News of North Caucasus. 2023;18(2):219-225. https://doi.org/10.14300/mnnc.2023.18052
7. Roeb E. Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol. 2018;68-69:463-473. https://doi.org/10.1016/j.matbio.2017.12.012
8. Lam S., Singh R., Dillman J. R., Trout A. T., Serai S. D. [et al.]. Serum matrix metalloproteinase 7 is a diagnostic biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease. Hepatol. Commun. 2020;4(11):1680-1693. https://doi.org/10.1002/hep4.1589
9. Irvine K. M., Okano S., Patel P. J., Horsfall L. U., Williams S. [et al.]. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non‑alcoholic fatty liver disease. Sci Rep. 2021;11(1):2858. https://doi.org/10.1038/s41598-021-82315-z
10. Kerola A., Lampela H., Lohi J., Heikkilla P., Mutanen A. [et al.]. Increased MMP-7 expression in biliary epithelium and serum underpins native liver fibrosis after successful portoenterostomy in biliary atresia. J. Path. Clin. Res. 2016;2:187-198. https://doi.org/10.1002/cjp2.50
11. Busk T. M., Bendtsen F., Nielsen H. J., Jensen V., Brünner N. [et al.]. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scand. J. Gastroenterol. 2014;49(9):1103-1110. https://doi.org/10.3109/00365521.2014.934910
12. Huang C.-Y., Tseng K.-C., Lin M.-N., Tsai J.-P., Su C.-C. Plasma levels of matrix metalloproteinase-2 and -9 in male and female patients with cirrhosis of different aetiologies. J. Clin. Pathol. 2015;68:917-922. https://doi.org/10.1136/jclinpath-2015-202932
13. Kwon O. S., Jung H. S., Bae K. S., Jung Y. K., Kim Y. S. [et al.]. Increased serum activity of matrix metalloproteinase-9 in patients with acute variceal bleeding. Gut Liver. 2012;6(2):249-255. https://doi.org/10.5009/gnl.2012.6.2.249
14. Metwally K., Fouad T., Shible N., Zaghla H., Sameea E. A. [et al.]. Metalloproteinase inhibitor-1 closely correlates with the severity of liver disease in Egyptian patients. J. Liver Dis. Transplant. 2017;6(4):1000157. https://doi.org/10.4172/2325-9612.1000157
15. Prystupa A., Boguszewska-Czubara A., Bojarska-Junak A., Torun-Jurkowska A., Rolinski J. [et al.]. Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. Ann. Agric. Environ. Med. 2015;22:325-328. https://doi.org/10.5604/12321966.1152088
16. Prystupa A., Szpetnar M., Boguszewska-Czubara A., Grzybowski A., Sak J. [et al.]. Activity of MMP1 and MMP13 and amino acid metabolism in patients with alcoholic liver cirrhosis. Med. Sci. Monitor. 2015;21:1008-1014. https://doi.org/10.12659/MSM.892312
17. Yu D., Li Y., Xu Y., Tang J., Li K. [et al.]. Dysregulated matrix metalloproteinases and tissue inhibitors of metalloproteinase in residual splenic tissue after subtotal splenectomy due to portal hypertension. Int. J. Clin. Exp. Pathol. 2017;10(2):1273-1282.
18. Moriya K., Nishimura N., Namisaki T., Takaya H., Sawada Y. [et al.]. Zinc administration and improved serum markers of hepatic fibrosis in patients with autoimmune hepatitis. J. Clin. Med. 2021;10:2465. https://doi.org/10.3390/jcm10112465
19. Wang X., Maretti-Mira A. C., Wang L., Deleve L. D. Liver-selective MMP-9 inhibition in the rat eliminates ischemia-reperfusion injury and accelerates liver regeneration. Hepatology. 2019;69:314-328. https://doi.org/10.1002/hep.30169
20. Behairy O. G., El-Bakry M. M., Mansour A. I., Abdelrahman A. M. N., Emam G. M. Matrix metalloproteinase-1 as a non-invasive biomarker to assess liver fibrosis in children with chronic liver disease. Egypt. Liver J. 2021;11:80. https://doi.org/10.1186/s43066-021-00148-x
21. Cui N., Hu M., Khalil R. A. Biochemical and biological attributes of matrix metalloproteinases. Prog. Mol. Biol. Transl. Sci. 2017;147:1-73. https://doi.org/10.1016/bs.pmbts.2017.02.005
22. Naim A., Pan Q., Baig M. S. Matrix metalloproteinases (MMPs) in liver diseases. J. Clin. Exp. Hepatol. 2017;7:367-372. https://doi.org/10.1016/j.jceh.2017.09.004
23. Roderfeld M. Matrix metalloproteinase functions in hepatic injury and fibrosis. Matrix Biol. 2018;68-69:452-462. https://doi.org/10.1016/j.matbio.2017.11.011
24. Wu J.-F., Jeng Y.-M., Chen H.-L., Ni Y.-H., Hsu H.-Y. [et al.]. Quantification of serum matrix metallopeptide 7 levels may assist in the diagnosis and predict the outcome for patients with biliary atresia. J. Pediatr. 2019;208:30-37. https://doi.org/10.1016/j.jpeds.2018.12.006
25. Yan L., Wang J., Hu X., Xu Y., Li K. [et al.]. Imbalance in matrix metalloproteinases and tissue inhibitor of metalloproteinases from splenic veins and great saphenous veins under high hemodynamics. Phlebology. 2020;35(1):18-26. https://doi.org/10.1177/0268355519842432
26. Serralheiro P., Cairrao E., Maia C. J., João M., Almeida C. M. C. [et al.]. Effect of TGFbeta1 on MMP/TIMP and TGF-beta1 receptors in great saphenous veins and its significance on chronic venous insufficiency. Phlebology. 2017;32:334-341. https://doi.org/10.1177/0268355516655067
27. Yi F., Chen J., Su M., Deng C., Zeng Z. [et al.]. Clinical value of differential diagnosis of matrix metalloproteinase-3 in benign and malignant hydrothorax and ascites. Chinese J. Lab. Med. 2019;12:776-781.
28. Shuna S., Ping L., Junfei W. Expression levels of matrix metalloproteinases in ascites of patients with ovarian cancer and the relationship with pathological characteristics of ovarian cancer. Discuss. Clin. Cases. 2019;6(2):12-16. https://doi.org/10.5430/dcc.v6n2p12
29. Hori T., Uemoto S., Walden L. B., Chen F., Baine A.-M. T. [et al.]. Matrix metalloproteinase-9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy: a pilot study in mice. Hepatol. Res. 2014;44:651-662. https://doi.org/10.1111/hepr.12161

Keywords: liver cirrhosis, complications, matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases